Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns

OncoImmunology

Volumn 6, Issue 8, 2017, Pages

  Nikanjam, Mina ^a   Patel, Harsh ^b   Kurzrock, Razelle ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Immunotherapy; maximum tolerated dose; precision medicine; recommended phase 2 dose; targeted therapy

Indexed keywords

ATEZOLIZUMAB; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DEXAMETHASONE; DOCETAXEL; DURVALUMAB; ETOPOSIDE; FLUOROURACIL; IPILIMUMAB; LENALIDOMIDE; NIVOLUMAB; PACLITAXEL; PEGINTERFERON ALPHA2B; PEMBROLIZUMAB; PEMETREXED; POMALIDOMIDE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TRAMETINIB;

ARTICLE; CYTOTOXICITY; HUMAN; IMMUNITY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; RESPONSE RATE; SMALL CELL LUNG CANCER; STOMACH CANCER;

EID: 85023748608     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1338997     Document Type: Article

References (40)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4):252-64; PMID:4856023; https://doi.org/10.1038/nrc3239
2. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33(17):1889-94; PMID:5089162; https://doi.org/10.1200/JCO.2014.56.2736
3. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002):a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16(8):908-18; https://doi.org/10.1016/S1470-2045(15)00083-2
4. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Jr, Lao CD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037):a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16(4):375-84; https://doi.org/10.1016/S1470-2045(15)70076-8
5. Herzberg B, Campo MJ, Gainor JF. Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist 2017; 22(1):81-8; https://doi.org/10.1634/theoncologist.2016-0189
6. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive non-small-cell lung cancer. N Engl J Med 2016; 375(19):1823-33; https://doi.org/10.1056/NEJMoa1606774
7. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373(2):123-35; PMID:4681400; https://doi.org/10.1056/NEJMoa1504627
8. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372(26):2509-20; PMID:4481136; https://doi.org/10.1056/NEJMoa1500596
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26):2443-54; PMID:3544539; https://doi.org/10.1056/NEJMoa1200690
10. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372(4):311-9; PMID:4348009; https://doi.org/10.1056/NEJMoa1411087
11. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348(6230):124-8; PMID:4993154; https://doi.org/10.1126/science.aaa1348
12. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371(23):2189-99; PMID:4315319; https://doi.org/10.1056/NEJMoa1406498
13. Ikeda S, Goodman AM, Cohen PR, Jensen TJ, Ellison CK, Frampton G, Miller V, Patel SP, Kurzrock R. Metastatic basal cell carcinoma with amplification of PD-L1:exceptional response to anti-PD1 therapy. NPJ Genom Med 2016; 1; PMID:27942391; https://doi.org/10.1038/npjgenmed.2016.37
14. Khagi Y, Kurzrock R, Patel SP. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev 2017 Mar; 36(1):179-190; PMID:27873079; https://doi.org/10.1007/s10555-016-9652-y
15. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther 2015; 14(4):847-56; https://doi.org/10.1158/1535-7163.MCT-14-0983
16. Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol 2016; https://doi.org/10.1038/nrclinonc.2016.168
17. Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). http://www.fda.gov/downloads/Drugs/…/Guidances/UCM078932.pdf. 2005
18. Le Tourneau C, Stathis A, Vidal L, Moore MJ, Siu LL. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. J Clin Oncol 2010; 28(8):1401-7; https://doi.org/10.1200/JCO.2009.25.9606
19. Liu S, Nikanjam M, Kurzrock R. Dosing de novo combinations of two targeted drugs:Towards a customized precision medicine approach to advanced cancers. Oncotarget 2016; 7(10):11310-20; PMID:4905475; https://doi.org/10.18632/oncotarget.7023
20. Nikanjam M, Liu S, Yang J, Kurzrock R. Dosing Three-drug combinations that include targeted anti-cancer agents:Analysis of 37,763 Patients. Oncologist 2017; 22(5):576-84; PMID:5423521; https://doi.org/10.1634/theoncologist.2016-0357
21. Nikanjam M, Liu S, Kurzrock R. Dosing targeted and cytotoxic two-drug combinations:Lessons learned from analysis of 24,326 patients reported 2010 through 2013. Int J Cancer 2016; 139(9):2135-41; PMID:5096042; https://doi.org/10.1002/ijc.30262
22. Tseng CW, Hung CF, Alvarez RD, Trimble C, Huh WK, Kim D, Chuang CM, Lin CT, Tsai YC, He L, et al. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 2008; 14(10):3185-92; PMID:3066100; https://doi.org/10.1158/1078-0432.CCR-08-0037
23. Zhu Y, Liu N, Xiong SD, Zheng YJ, Chu YW. CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4. Scand J Immunol 2011; 73(4):301-8; https://doi.org/10.1111/j.1365-3083.2011.02514.x
24. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response:implications for combination chemo-immunotherapy. Cancer Res 2002; 62(8):2353-8
25. Wu L, Yun Z, Tagawa T, Rey-McIntyre K, de Perrot M. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther 2012; 11(8):1809-19; https://doi.org/10.1158/1535-7163.MCT-11-1014
26. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38(4):729-41; https://doi.org/10.1016/j.immuni.2013.03.003
27. Hughes PE, Caenepeel S, Wu LC. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends Immunol 2016; 37(7):462-76; https://doi.org/10.1016/j.it.2016.04.010
28. Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med 2014; 11(4):237-46; PMID:4296084; https://doi.org/10.7497/j.issn.2095-3941.2014.04.002
29. Melero I, Berman DM, Aznar MA, Korman AJ, Perez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015; 15(8):457-72; https://doi.org/10.1038/nrc3973
30. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res 2015; 21(19):4286-93; https://doi.org/10.1158/1078-0432.CCR-14-2607
31. Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer 2017; 75:47-55; https://doi.org/10.1016/j.ejca.2017.01.009
32. Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL, Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064):an open-label, randomised, phase 2 trial. Lancet Oncol 2016; 17(7):943-55; https://doi.org/10.1016/S1470-2045(16)30126-7
33. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, Wheler J, Kurzrock R. Phase I oncology studies:evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 2010; 16(4):1289-97; PMID:2822881; https://doi.org/10.1158/1078-0432.CCR-09-2684
34. Gupta S, Hunsberger S, Boerner SA, Rubinstein L, Royds R, Ivy P, LoRusso P. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst 2012; 104(24):1860-6; https://doi.org/10.1093/jnci/djs439
35. Borad MJ, Curtis KK, Babiker HM, Benjamin M, Tibes R, Ramanathan RK, Wright K, Dueck AC, Jameson G, Von Hoff DD. The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials. J Cancer 2012; 3:345-53; PMID:3434362; https://doi.org/10.7150/jca.4714
36. Alvim MM, Silva LA, Leite IC, Silverio MS. Adverse events caused by potential drug-drug interactions in an intensive care unit of a teaching hospital. Rev Bras Ter Intensiva 2015; 27(4):353-9; PMID:4738821; https://doi.org/10.5935/0103-507X.20150060
37. Pichala PT, Kumar BM, Zachariah S, Thomas D, Saunchez L, Gerardo AU. An interventional study on intensive care unit drug therapy assessment in a rural district hospital in India. J Basic Clin Pharm 2013; 4(3):64-7; PMID:3979274; https://doi.org/10.4103/0976-0105.118801
38. Tavallaee M, Fahimi F, Kiani S. Drug-use patterns in an intensive care unit of a hospital in Iran:an observational prospective study. Int J Pharm Pract 2010; 18(6):370-6; https://doi.org/10.1111/j.2042-7174.2010.00065.x
39. Hamberg P, Verweij J. Phase I drug combination trial design:walking the tightrope. J Clin Oncol 2009; 27(27):4441-3; https://doi.org/10.1200/JCO.2009.23.6703
40. Hamberg P, Ratain MJ, Lesaffre E, Verweij J. Dose-escalation models for combination phase I trials in oncology. Eur J Cancer. 2010; 46(16):2870-8; https://doi.org/10.1016/j.ejca.2010.07.002